| The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer M Knauer, S Mook, EJT Rutgers, RA Bender, M Hauptmann, ... Breast cancer research and treatment 120, 655-661, 2010 | 337 | 2010 |
| Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER) JM Bueno-de-Mesquita, WH van Harten, VP Retel, LJ van't Veer, ... The lancet oncology 8 (12), 1079-1087, 2007 | 333 | 2007 |
| A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study CA Drukker, JM Bueno‐de‐Mesquita, VP Retèl, WH van Harten, ... International journal of cancer 133 (4), 929-936, 2013 | 283 | 2013 |
| Validation of 70-gene prognosis signature in node-negative breast cancer JM Bueno-de-Mesquita, SC Linn, R Keijzer, J Wesseling, DSA Nuyten, ... Breast cancer research and treatment 117, 483-495, 2009 | 212 | 2009 |
| Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer P Roepman, HM Horlings, O Krijgsman, M Kok, JM Bueno-de-Mesquita, ... Clinical Cancer Research 15 (22), 7003-7011, 2009 | 120 | 2009 |
| Technology Insight: tuning into the genetic orchestra using microarrays—limitations of DNA microarrays in clinical practice A Abdullah-Sayani, JM Bueno-de-Mesquita, MJ Van De Vijver Nature clinical practice Oncology 3 (9), 501-516, 2006 | 104 | 2006 |
| Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature S Mook, M Knauer, JM Bueno-de-Mesquita, VP Retel, J Wesseling, ... Annals of surgical oncology 17, 1406-1413, 2010 | 101 | 2010 |
| Methodology of constructive technology assessment in health care KFL Douma, K Karsenberg, MJM Hummel, JM Bueno-de-Mesquita, ... International journal of technology assessment in health care 23 (2), 162-168, 2007 | 82 | 2007 |
| The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment JM Bueno-de-Mesquita, DSA Nuyten, J Wesseling, H van Tinteren, ... Annals of oncology 21 (1), 40-47, 2010 | 79 | 2010 |
| Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics VP Retèl, JM Bueno-de-Mesquita, MJM Hummel, MJ van de Vijver, ... International journal of technology assessment in health care 25 (1), 73-83, 2009 | 40 | 2009 |
| Prospective cost-effectiveness analysis of genomic profiling in breast cancer VP Retel, MA Joore, CA Drukker, JM Bueno-de-Mesquita, M Knauer, ... European journal of cancer 49 (18), 3773-3779, 2013 | 36 | 2013 |
| Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice JM Bueno-de-Mesquita, GS Sonke, MJ van de Vijver, SC Linn Annals of oncology 22 (9), 2021-2030, 2011 | 34 | 2011 |
| Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms CA Drukker, MV Nijenhuis, JM Bueno-de-Mesquita, VP Retèl, ... Breast cancer research and treatment 145, 697-705, 2014 | 31 | 2014 |
| 0073 The 70-gene MammaPrint signature is predictive for chemotherapy benefit in early breast cancer M Knauer, M Straver, E Rutgers, R Bender, F Cardoso, S Mook, ... The Breast, S36-S37, 2009 | 12 | 2009 |
| A new independent validation of the 70-gene signature in node-negative breast cancer JMB de Mesquita, SC Linn, AAM Hart, C Van Krimpen, C Meijers, ... EJC Supplements 2 (4), 131, 2006 | 7 | 2006 |
| Identification of a low risk subgroup in Her2-positive breast cancer by the 70-gene prognosis signature. M Knauer, F Cardoso, S Mook, P Bedard, R Koornstra, M Kok, ... Cancer Research 69 (2_Supplement), 4171, 2009 | 5 | 2009 |
| Use of a 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based study (RASTER) JM de Mesquita, HWH Bueno, VP Retel Lancet Oncol 8, 1079-1087, 2007 | 5 | 2007 |
| 10 years follow up of the RASTER study; implementing a genomic signature in daily practice SB Vliek, V Retel, C Drukker, E Rutgers, H van Tinteren, MJ Van de Vijver, ... Annals of Oncology 28, v46, 2017 | 4 | 2017 |
| Microarraybased readout of ER, PR, and HER2 expression in breast cancer tissue P Roepman, HM Horlings, O Krijgsman, M Kok, R Koornstra, ... ASCO Breast Cancer Symposium, 102, 2008 | 4 | 2008 |
| Feasibility of gene expression profiling in community hospitals; preliminary results of a pilot study in N0 breast cancer patients JM Bueno de Mesquita, MJ Van De Vijver, JL Peterse Breast Cancer Res. Treat 94, A309, 2005 | 4 | 2005 |
Sabine LinnProfessor of Translational Oncology - Utrecht University; Group leader NKI AmsterdamVerified email at nki.nl
